Last reviewed · How we verify
Ongoing cART regimen
cART regimens combine multiple antiretroviral drugs to suppress HIV replication by targeting different stages of the viral life cycle.
cART regimens combine multiple antiretroviral drugs to suppress HIV replication by targeting different stages of the viral life cycle. Used for HIV-1 infection.
At a glance
| Generic name | Ongoing cART regimen |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | Antiretroviral |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
cART regimens typically consist of a combination of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase strand transfer inhibitors (INSTIs). These drugs work by inhibiting viral enzymes necessary for viral replication, thereby reducing the viral load in the body.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Insomnia
- Rash
- Abdominal pain
- Dizziness
- Muscle pain
Key clinical trials
- More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (PHASE1, PHASE2)
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (PHASE1)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients (PHASE4)
- Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (PHASE3)
- Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART (PHASE1, PHASE2)
- Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV) (PHASE4)
- A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ongoing cART regimen CI brief — competitive landscape report
- Ongoing cART regimen updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI